HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

North America Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


North America Hepatic Encephalopathy Treatment Market Insights

  • Reed Intelligence analysis indicates that the North America Hepatic Encephalopathy Treatment Market size, which was USD 930.98 Million in 2025, is projected to attain USD 1974.06 Million by 2034.
  • The market is expected to register a CAGR of 8.6% over the period 2026–2034.
  • In 2025, Rifaximin emerged as the dominant Drug Class based on market size.
  • Rifaximin is projected to register the fastest growth, positioning it as the most attractive Drug Class segment over the forecast horizon.

Other Key Findings


  • In 2025, North America contributed 37.54% to the overall global Hepatic Encephalopathy Treatment Market size.
  • By 2034, United States is anticipated to dominate the global market based on market size.
  • United States is expected to witness the fastest growth within North America, attaining USD 1573.4 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 930.98 Million
Market Size In 2034 USD 1974.06 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 8.6% (2026-2034)
Segmnetation Covered
North America
  1. United States
  2. Canada
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports